查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1611040

生物製藥第三方物流市場規模、佔有率、趨勢分析報告：依供應鏈、按服務類型、按地區、細分市場預測，2025-2030年

Biopharmaceutical Third-party Logistics Market Size, Share & Trends Analysis Report By Supply Chain (Cold Chain Logistics, Non-cold Chain Logistics), By Service Type (Transportation, Warehousing & Storage), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 160 Pages | 商品交期: 2-10個工作天內

價格

生物製藥第三方物流市場成長與趨勢

Grand View Research, Inc.的最新報告顯示，到2030年，全球生物製藥第三方物流市場規模預計將達到2,090億美元。預計2025年至2030年該市場將以6.58%的複合年成長率成長。對跨地區運輸生技藥品的溫控物流服務的需求不斷增加，以及生物製藥公司擴大分銷網路以提高銷售隊伍，這是推動市場成長的因素。新興國家擴大採用自動化儲存和搜尋系統是一個持續的趨勢，也是製藥物流公司的主要驅動力。

此外，從小分子藥物轉型為生技藥品）的趨勢預計將推動市場。由於這些小分子藥物是溫度敏感產品，對溫控運輸和儲存的需求不斷增加，促進了市場成長。技術進步是推動市場成長的關鍵因素之一。行動雲端解決方案、倉庫機器人和資料探勘等技術已經改變了整個 3PL 領域。借助這些先進技術，3PL 公司能夠在運輸過程中保持產品所需的溫度。

這降低了產品複雜性和人為錯誤。大多數生物藥品對溫度非常敏感，必須在要求的溫度下儲存。此類產品需要追蹤設備進行監控直至交付。例如，2023年5月，Tridentify推出了具有創新能力的即時低溫運輸監控系統，能夠持續追蹤低溫運輸中運輸的產品的穩定性和剩餘保存期限。該系統有望透過提供有關藥物穩定性和剩餘保存期限的即時詳細資訊，徹底改變公司監控業務和管理穩定性預算的方式。

此外，出於環境考量和成本考慮，商業產品的運輸方式逐漸從空運轉向海運，道路運輸從卡車轉向多式聯運（鐵路和卡車）。這些製藥公司主要使用多式聯運來減少碳排放。從目前的趨勢來看，藥品製造商正在轉向海運，以降低成本和風險因素。對於低溫運輸產品，企業還是更青睞航空運輸。然而，一些大型製藥公司計劃透過海運運輸其70%的產品，其中包括低溫運輸產品。

生物製藥第三方物流市場報告亮點

  • 2024年，由於不需要溫度控制的藥品數量龐大，非低溫運輸物流領域佔銷售額的最大佔有率為79.7%。
  • 由於對細胞療法、疫苗和檢測套組等生技藥品的需求，低溫運輸物流領域預計在預測期內複合年成長率為 9.40%。
  • 倉儲領域佔比最大，2024年將達43.3%。由於公司內部能力不足，2024年運輸部門也佔了很大的收益佔有率。
  • 由於生物製藥進出口增加，2024年北美地區收益佔有率最大，超過42.53%。
  • 由於人口老化以及藥品銷售從品牌製造商轉向非專利製造商的轉變，預計亞太地區在預測期內的複合年成長率將達到 7.4%，是最快的。
  • 主要企業正在採取多項策略措施來提高其在市場上的影響力。例如，2021年2月，德迅與中國最大的非國有藥品分銷公司九州通建立夥伴關係，以加強其在中國的醫療醫藥物流足跡。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章生物製藥第三方物流市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/補充市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
    • 市場問題分析
  • 市場分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第4章生物製藥第三方物流市場：供應鏈、估算與趨勢分析

  • 細分儀表板
  • 全球生物醫藥第三方物流市場、供應鏈波動分析
  • 2018-2030年全球生物製藥第三方物流規模及趨勢分析（依供應鏈）
  • 低溫運輸物流
  • 非低溫運輸物流

第5章生物製藥第三方物流市場：服務類型、估算與趨勢分析

  • 細分儀表板
  • 全球生物醫藥第三方物流市場、服務類型變化分析
  • 2018-2030年全球生物製藥第三方物流規模及趨勢分析（依服務類型）
  • 運輸
    • 航空貨運
    • 海運
    • 陸上
  • 倉庫/倉儲
  • 其他

第6章生物製藥第三方物流市場：區域、估計與趨勢分析

  • 2024 年及 2030 年按地區分類的市場佔有率分析
  • 區域市場儀表板
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 公司分類
  • 2024 年企業市場分析
  • 公司簡介
    • DHL International GmbH
    • SF Express
    • FedEx
    • United Parcel Service of America, Inc.
    • Cencora, Inc
    • DB Schenker
    • Kuehne and Nagel
    • Kerry Logistics Network Limited
    • Agility Public Warehousing Company KSCP
Product Code: GVR-2-68038-773-5

Biopharmaceutical Third-party Logistics Market Growth & Trends:

The global biopharmaceutical third-party logistics market size is anticipated to reach USD 209.0 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 6.58% from 2025 to 2030. Increasing demand for temperature-controlled logistic services to transport biologics in various regions and growing distribution networks of biopharmaceutical companies to improve their sales are factors driving the market growth. The rising adoption of automated storage and retrieval systems in emerging countries is an ongoing trend among pharmaceutical logistics companies that has gained significant traction.

Furthermore, the trend of shifting from small-molecule drugs to biopharmaceuticals, mainly vaccines and biologics, is projected to drive the market. Since, these small molecule drugs are temperature-sensitive products, demand for temperature-controlled transportation and storage increases and thus, is responsible for the market growth. Technological advancements are among the main factors drivingmarket growth. Technologies, such as mobile cloud solutions, warehouse robotics, and data mining, have changed the overall 3PL space. With the help of these advanced technologies, 3PL companies can maintain the required temperatures for products during transportation.

This will help in reducing complexities in products and human errors. Most biopharmaceutical products are very temperature-sensitive and hence should be stored at the required temperatures. These products require a tracking device for monitoring until delivery. For instance, in May 2023, Tridentify launched a real-time cold chain monitoring system with an innovative feature for continuously tracking the stability and remaining shelf life of products transported in the cold chain. It offers a thorough view of the stability and remaining shelf-life of pharmaceutical products in real-time, which will revolutionize the way companies monitor their operations and manage their stability budgets.

In addition, environmental concerns and costs have caused a slight shift in the means of transport used for commercial products, moving from airway to seaway shipping and in roadways from truck to intermodal (both rail and truck) transport. Intermodal transport is majorly used by these pharmaceutical companies to reduce their carbon footprint. The ongoing trend shows that pharmaceutical manufacturers have shifted to sea freight to reduce the cost and risk factors. Although for cold chain products, the companies still prefer air freight. However, some of the large pharmaceutical companies are planning to transport 70% of their products via ocean freight including cold chain products.

Biopharmaceutical Third-party Logistics Market Report Highlights:

  • In 2024, the non-cold chain logistics segment held the largest share of 79.7% in terms of revenue owing to the sales of a large number of drugs that do not require any temperature control.
  • The cold chain logistics segment is expected to register a CAGR of 9.40% over the forecast period owing to the demand for biologics, such as cellular therapies, vaccines, and test kits.
  • The warehousing and storage segment held the largest share of 43.3% in 2024. The transportation segment also held a significant revenue share in 2024 due to the lack of internal capabilities of companies.
  • North America held the largest revenue share of over 42.53% in 2024 owing to the rise in imports and exports for biopharmaceutical in the country.
  • Asia Pacific is expected to register the fastest CAGR of 7.4% over the forecast period owing to the adoption of medicines from the aging population and the shift of drug sales from brand manufacturers to generic.
  • The key players are undertaking several strategic initiatives to strengthen their market presence. For instance, in February 2021, Kuehne+Nagel entered into a partnership with China's largest non-state-owned pharma distribution company, Jointown, to enhance its footprint in healthcare & pharmaceutical logistics in China.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis
    • 1.6.2. Bottom-up Approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Biopharmaceutical Third-Party Logistics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Technological advancements in logistics
      • 3.2.1.2. Growing applications of reverse logistics in biopharmaceutical industry
      • 3.2.1.3. Rising demand for cold chain logistics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Compliance issues while outsourcing
      • 3.2.2.2. Stringent regulatory framework
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenges Analysis
  • 3.3. Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Biopharmaceutical Third-Party Logistics Market: Supply Chain Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Biopharmaceutical Third-Party Logistics Market; Supply Chain Movement Analysis
  • 4.3. Global Biopharmaceutical Third-Party Logistics Size & Trend Analysis, by Supply Chain, 2018 to 2030 (USD Million)
  • 4.4. Cold Chain Logistics
    • 4.4.1. Cold Chain Logistics market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Non-cold Chain Logistics
    • 4.5.1. Non-cold Chain Logistics market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Biopharmaceutical Third-Party Logistics Market: Service Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Biopharmaceutical Third-Party Logistics Market; Service Type Movement Analysis
  • 5.3. Global Biopharmaceutical Third-Party Logistics Size & Trend Analysis, by Service Type, 2018 to 2030 (USD Million)
  • 5.4. Transportation
    • 5.4.1. Transportation market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Air Freight
      • 5.4.2.1. Air freight market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Sea Freight
      • 5.4.3.1. Sea freight market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Overland
      • 5.4.4.1. Overland market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Warehousing and Storage
    • 5.5.1. Warehousing and storage market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Other Services
    • 5.6.1. Other services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Biopharmaceutical Third-Party Logistics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. North America
    • 6.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Competitive scenario
      • 6.3.2.3. Regulatory framework
      • 6.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Competitive scenario
      • 6.3.3.3. Regulatory framework
      • 6.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.4. Mexico
      • 6.3.4.1. Key country dynamics
      • 6.3.4.2. Competitive scenario
      • 6.3.4.3. Regulatory framework
      • 6.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.4.2. UK
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Competitive scenario
      • 6.4.2.3. Regulatory framework
      • 6.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Germany
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Competitive scenario
      • 6.4.3.3. Regulatory framework
      • 6.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. France
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Competitive scenario
      • 6.4.4.3. Regulatory framework
      • 6.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Italy
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Competitive scenario
      • 6.4.5.3. Regulatory framework
      • 6.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Spain
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Competitive scenario
      • 6.4.6.3. Regulatory framework
      • 6.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Denmark
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Competitive scenario
      • 6.4.7.3. Regulatory framework
      • 6.4.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Sweden
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Competitive scenario
      • 6.4.8.3. Regulatory framework
      • 6.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.9. Norway
      • 6.4.9.1. Key country dynamics
      • 6.4.9.2. Competitive scenario
      • 6.4.9.3. Regulatory framework
      • 6.4.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Japan
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Competitive scenario
      • 6.5.2.3. Regulatory framework
      • 6.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. China
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Competitive scenario
      • 6.5.3.3. Regulatory framework
      • 6.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. India
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Competitive scenario
      • 6.5.4.3. Regulatory framework
      • 6.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. Australia
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Competitive scenario
      • 6.5.5.3. Regulatory framework
      • 6.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Competitive scenario
      • 6.5.6.3. Regulatory framework
      • 6.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.7. Thailand
      • 6.5.7.1. Key country dynamics
      • 6.5.7.2. Competitive scenario
      • 6.5.7.3. Regulatory framework
      • 6.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Brazil
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Competitive scenario
      • 6.6.2.3. Regulatory framework
      • 6.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Competitive scenario
      • 6.6.3.3. Regulatory framework
      • 6.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Competitive scenario
      • 6.7.2.3. Regulatory framework
      • 6.7.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. Saudi Arabia
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Competitive scenario
      • 6.7.3.3. Regulatory framework
      • 6.7.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. UAE
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Competitive scenario
      • 6.7.4.3. Regulatory framework
      • 6.7.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. Kuwait
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Competitive scenario
      • 6.7.5.3. Regulatory framework
      • 6.7.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Company Market Position Analysis, 2024
  • 7.3. Company Profiles
    • 7.3.1. DHL International GmbH
      • 7.3.1.1. Company overview
      • 7.3.1.2. Financial performance
      • 7.3.1.3. Service benchmarking
      • 7.3.1.4. Strategic initiatives
    • 7.3.2. SF Express
      • 7.3.2.1. Company overview
      • 7.3.2.2. Financial performance
      • 7.3.2.3. Service benchmarking
      • 7.3.2.4. Strategic initiatives
    • 7.3.3. FedEx
      • 7.3.3.1. Company overview
      • 7.3.3.2. Financial performance
      • 7.3.3.3. Service benchmarking
      • 7.3.3.4. Strategic initiatives
    • 7.3.4. United Parcel Service of America, Inc.
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Service benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Cencora, Inc
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Service benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. DB Schenker
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Service benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Kuehne and Nagel
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Service benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Kerry Logistics Network Limited
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Service benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Agility Public Warehousing Company K.S.C.P.
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Service benchmarking
      • 7.3.9.4. Strategic initiatives

List of Tables

  • Table 1 List of Tables
  • Table 2 List of Secondary Sources
  • Table 3 List of Abbreviations
  • Table 4 Global Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 5 Global Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 6 Global Biopharmaceutical Third-Party Logistics, by Region, 2018 - 2030 (USD Million)
  • Table 7 North America Biopharmaceutical Third-Party Logistics, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 9 North America Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 10 U.S. Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 11 U.S. Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 12 Canada Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 13 Canada Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 14 Mexico Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 15 Mexico Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 16 Europe Biopharmaceutical Third-Party Logistics, by Country, 2018 - 2030 (USD Million)
  • Table 17 Europe Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 18 Europe Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 19 UK Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 20 UK Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 21 Germany Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 22 Germany Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 23 France Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 24 France Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 25 Italy Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 26 Italy Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 27 Spain Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 28 Spain Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 29 Denmark Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 30 Denmark Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 31 Sweden Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 32 Sweden Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 33 Norway Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 34 Norway Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Biopharmaceutical Third-Party Logistics, by Country, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 37 Asia Pacific Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 38 Japan Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 39 Japan Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 40 China Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 41 China Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 42 India Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 43 India Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 44 Thailand Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 45 Thailand Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 46 South Korea Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 47 South Korea Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 48 Australia Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 49 Australia Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 50 Latin America Biopharmaceutical Third-Party Logistics, by Country, 2018 - 2030 (USD Million)
  • Table 51 Latin America Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 52 Latin America Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 53 Brazil Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 54 Brazil Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 55 Argentina Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 56 Argentina Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Biopharmaceutical Third-Party Logistics, by Country, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 59 Middle East & Africa Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 60 South Africa Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 61 South Africa Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 63 Saudi Arabia Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 64 UAE Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 65 UAE Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 67 Kuwait Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Biopharmaceutical Third-Party Logistics Market revenue, 2018 - 2030 (USD Million)
  • Fig. 10 Biopharmaceutical Third-Party Logistics Market snapshot
  • Fig. 11 Biopharmaceutical Third-Party Logistics Market driver impact
  • Fig. 12 Biopharmaceutical Third-Party Logistics Market restraint impact
  • Fig. 13 Biopharmaceutical Third-Party Logistics Market: Supply Chain takeaways (USD Million)
  • Fig. 14 Biopharmaceutical Third-Party Logistics Market: Supply Chain movement analysis
  • Fig. 15 Cold Chain Logistics market, 2018 - 2030 (USD Million)
  • Fig. 16 Non-cold Chain Logistics market, 2018 - 2030 (USD Million)
  • Fig. 17 Biopharmaceutical Third-Party Logistics Market: Service Type takeaways (USD Million)
  • Fig. 18 Biopharmaceutical Third-Party Logistics Market: Service Type movement analysis
  • Fig. 19 Transportation market, 2018 - 2030 (USD Million)
  • Fig. 20 Air Freight market, 2018 - 2030 (USD Million)
  • Fig. 21 Sea Freight market, 2018 - 2030 (USD Million)
  • Fig. 22 Overland market, 2018 - 2030 (USD Million)
  • Fig. 23 Warehousing and Storage market, 2018 - 2030 (USD Million)
  • Fig. 24 Other Services market, 2018 - 2030 (USD Million)
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 Regional outlook, 2024 & 2030
  • Fig. 27 North America Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 29 Canada Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 30 Mexico Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 31 Europe Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 32 UK Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 33 Germany Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 34 France Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 35 Italy Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 36 Spain companion animal Health market, 2018 - 2030 (USD Million)
  • Fig. 37 Sweden Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 38 Denmark Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 39 Norway Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 40 Asia Pacific Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 41 Japan Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 42 China Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 43 India Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 44 Thailand Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 45 South Korea Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 46 Australia Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 47 Latin America Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 48 Brazil Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 49 Argentina Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 50 Middle East & Africa Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 51 South Africa Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 52 Saudi Arabia Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 53 UAE Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 54 Kuwait Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 55 Market participant categorization